<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494637</url>
  </required_header>
  <id_info>
    <org_study_id>L06.10.058</org_study_id>
    <nct_id>NCT00494637</nct_id>
  </id_info>
  <brief_title>The Use of Sodium Bicarbonate in the Prevention of Contrast Induced Nephropathy</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lenox Hill Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lenox Hill Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary studies have shown a benefit of sodium bicarbonate infusion in decreasing the
      risk of contrast induced nephropathy with coronary angiography. The investigators plan to
      randomize 478 patients (with serum creatinine 1.5 mg/dl or greater) undergoing coronary
      angiography to intravenous isotonic saline or intravenous isotonic sodium bicarbonate
      beginning one hour before the procedure and for four hours after. The primary endpoint is the
      development of contrast nephropathy within 48-72 hours after the procedure. Patients with an
      ejection fraction &lt;30%, overt CHF, hypokalemia and alkalemia will be excluded.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Not reaching recruitment and endpoint goals
  </why_stopped>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of contrast induced nephropathy</measure>
    <time_frame>48-72 hours</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">468</enrollment>
  <condition>Contrast Induced Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium bicarbonate</intervention_name>
    <description>isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  serum creatinine greater then or equal to 1.5

        Exclusion Criteria:

          -  EF&lt;30

          -  Overt CHF

          -  Alkalemia

          -  Hypokalemia

          -  GFR&lt;20 cc/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jordan L Rosenstock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lenox Hill Hospital</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2007</study_first_submitted>
  <study_first_submitted_qc>June 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2007</study_first_posted>
  <last_update_submitted>January 27, 2009</last_update_submitted>
  <last_update_submitted_qc>January 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Jordan L. Rosenstock, MD</name_title>
    <organization>Lenox Hill Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

